Exelixis to raise $160 million through two financing deals
This article was originally published in Scrip
Executive Summary
Exelixis has followed up its recent move to cut costs and tighten its focus on compounds in late-stage clinical development with agreements to raise an aggregate $160 million in capital through two separate financing deals.